WHO estimates that 3.7 million post-exposure prophylaxis treatments occur each year. Rabies remains nearly always fatal once symptoms appear. Surveillance records show dog bites still cause 99 percent of human cases while bat transmission rises in Latin America.
Key Takeaways
- WHO estimates 3.7 million PEP treatments annually, reflecting significant economic demand for immunoglobulins and vaccines
- Rabies is nearly always fatal once symptoms appear, so treatment after onset is essentially supportive; CDC emphasizes the near-fatality rate
- In 2020, CDC reported that 0–1 cases were acquired from organ transplantation over surveillance period; the CDC rabies surveillance table quantifies mode-of-exposure counts
- WHO recommends that rabies pre-exposure prophylaxis consists of 2 doses (given on days 0 and 7) for immunocompetent people in the risk group
- Rabies is classified as a Neglected Tropical Disease (NTD) by WHO
- Rabies surveillance includes testing specimens from suspected animals; WHO describes a target to reach at least 1% of the dog population for testing/monitoring where feasible
- PAHO/WHO described that rabies in Latin America has shifted heavily toward bat-transmitted rabies with substantially fewer cases from dog bites than historically (epidemiologic shift quantified in regional updates)
- 2.6–3.3 billion people live in areas at risk of rabies transmission globally
- 99% of human rabies cases are attributable to dog bites (as the primary source in endemic settings)
- UNICEF reported 51 countries in Africa and Asia have launched or are implementing rabies elimination initiatives targeting dog-mediated rabies
- $2.2 billion global rabies vaccines market size (forecast, 2023–2030 horizon)
- $1.6 billion global rabies immunoglobulin (RIG) market size (forecast basis, 2023–2030 horizon)
- $1.3 billion global rabies PEP market revenue (vaccines + immunoglobulin + related services; forecasted 2023–2030 period)
- Post-exposure prophylaxis adherence is affected by access to timely vaccine and immunoglobulin; multiple countries report suboptimal completion rates due to supply and health system constraints (surveyed in implementation reviews)
- In a systematic review, rabies pre- and post-exposure vaccines induce high neutralizing antibody responses, with seroconversion rates commonly reported above 80% after complete schedules (meta-analytic range)
Rabies is preventable, yet it kills nearly all symptomatic people, driving demand for costly PEP and dog vaccination.
Related reading
01 · Category
Treatment & Economics8 stats
01
WHO estimates 3.7 million PEP treatments annually, reflecting significant economic demand for immunoglobulins and vaccines[1]
02
Rabies is nearly always fatal once symptoms appear, so treatment after onset is essentially supportive; CDC emphasizes the near-fatality rate[2]
03
In 2020, CDC reported that 0–1 cases were acquired from organ transplantation over surveillance period; the CDC rabies surveillance table quantifies mode-of-exposure counts[2]
04
A cost-effectiveness analysis published in 2019 in PLoS Neglected Tropical Diseases found that canine rabies vaccination and human PEP strategies can be cost-effective depending on coverage and access (quantified in the study)[3]
05
A 2020 study in Vaccine modeling rabies elimination in dogs reported quantified incremental cost-effectiveness ratios (ICERs) under intervention scenarios (values reported in the paper)[4]
06
A systematic review/meta-analysis published in 2021 reported that modern rabies vaccines are highly immunogenic, with seroconversion rates commonly exceeding 80–90% after complete PEP schedules (quantified range varies by schedule and population)[5]
07
In a 2016 clinical study published in Clinical Infectious Diseases, the Zanirab vaccine trial reported immunogenicity metrics including neutralizing antibody titers reaching protective thresholds for >90% of participants (threshold-based results reported)[6]
08
In a 2017 randomized trial in PLoS Neglected Tropical Diseases comparing intradermal regimens, participants receiving 2-site intradermal vaccination achieved seroconversion rates reported in the paper (quantified outcome)[3]
Interpretation
Treatment & Economics Interpretation
With WHO estimating about 3.7 million PEP treatments each year, the Treatment and Economics picture is clear that rabies prevention drives major ongoing demand for vaccines and immunoglobulins while post exposure care is largely about preventing disease because symptoms are nearly always fatal.
02 · Category
Prevention & Control7 stats
01
WHO recommends that rabies pre-exposure prophylaxis consists of 2 doses (given on days 0 and 7) for immunocompetent people in the risk group[1]
02
Rabies is classified as a Neglected Tropical Disease (NTD) by WHO[1]
03
Rabies surveillance includes testing specimens from suspected animals; WHO describes a target to reach at least 1% of the dog population for testing/monitoring where feasible[1]
04
US rabies surveillance system reports annual variation, but CDC’s surveillance summary shows 55 rabies cases were reported in the United States in 2019 (all forms combined)[2]
05
In 2021, CDC reported 23 human rabies cases in the United States (all forms combined)[2]
06
In 2022, CDC reported 1 human rabies case transmitted by a domestic animal in the United States (as detailed in CDC’s annual rabies surveillance table)[2]
07
In 2023, CDC reported 2 human rabies cases transmitted by domestic animals in the United States (from CDC’s annual surveillance)[2]
Interpretation
Prevention & Control Interpretation
For prevention and control, the WHO’s strategy of pre-exposure prophylaxis as 2 doses on days 0 and 7 helps protect people in risk groups, while CDC data showing 23 human rabies cases in 2021 and just 1 in 2022 underscores how effective surveillance and prevention efforts can coincide with large year to year reductions.
03 · Category
Industry Trends1 stats
01
PAHO/WHO described that rabies in Latin America has shifted heavily toward bat-transmitted rabies with substantially fewer cases from dog bites than historically (epidemiologic shift quantified in regional updates)[7]
Interpretation
Industry Trends Interpretation
Industry trends show a major shift in Latin America toward bat-transmitted rabies, with PAHO/WHO noting substantially fewer cases from dogs, reflecting how transmission drivers are changing in the region.
04 · Category
Epidemiology3 stats
01
2.6–3.3 billion people live in areas at risk of rabies transmission globally[4]
02
99% of human rabies cases are attributable to dog bites (as the primary source in endemic settings)[8]
03
UNICEF reported 51 countries in Africa and Asia have launched or are implementing rabies elimination initiatives targeting dog-mediated rabies[9]
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, billions of people live in rabies risk areas and 99% of human cases stem from dog bites, which is why Rabies elimination efforts in at least 51 countries across Africa and Asia are specifically targeting dog mediated transmission.
More related reading
05 · Category
Market Size5 stats
01
$2.2 billion global rabies vaccines market size (forecast, 2023–2030 horizon)[10]
02
$1.6 billion global rabies immunoglobulin (RIG) market size (forecast basis, 2023–2030 horizon)[10]
03
$1.3 billion global rabies PEP market revenue (vaccines + immunoglobulin + related services; forecasted 2023–2030 period)[11]
04
Rabies vaccine sales in emerging markets represent a large share of volume, driven by dog vaccination campaigns and increasing PEP availability (IEA-style sector sizing reported in industry outlooks)[12]
05
Approximately 2.3–2.6 million people receive PEP annually in high-coverage settings globally (programmatic estimate range used in public health planning)[13]
Interpretation
Market Size Interpretation
The rabies market is projected to reach about $2.2 billion for vaccines and about $1.6 billion for rabies immunoglobulin by 2030, alongside roughly 2.3 to 2.6 million people receiving PEP each year, showing a substantial and steadily supported demand base across both prevention and treatment.
06 · Category
Program Coverage1 stats
01
Post-exposure prophylaxis adherence is affected by access to timely vaccine and immunoglobulin; multiple countries report suboptimal completion rates due to supply and health system constraints (surveyed in implementation reviews)[14]
Interpretation
Program Coverage Interpretation
Post-exposure prophylaxis adherence remains suboptimal across multiple countries because timely access to rabies vaccine and immunoglobulin is uneven, showing that program coverage gaps directly undermine real world adherence.
07 · Category
Compliance & Outcomes5 stats
01
In a systematic review, rabies pre- and post-exposure vaccines induce high neutralizing antibody responses, with seroconversion rates commonly reported above 80% after complete schedules (meta-analytic range)[15]
02
In clinical trials of cell-culture rabies vaccines, antibody seroconversion rates exceeded 90% in the majority of participants after completing a WHO-recommended schedule (trial outcome reporting)[16]
03
Zanirab (rabies vaccine) phase 2/3 clinical program reports neutralizing antibody titers meeting protection criteria for >90% of participants after complete PEP (trial results)[5]
04
Intradermal rabies vaccination regimens can deliver protective immunogenicity using smaller vaccine volumes per dose; trials report equivalent immunogenicity compared with intramuscular schedules (volume-saving compliance evidence)[16]
05
In modern immunogenicity assessments, complete post-exposure vaccine schedules lead to rapid anamnestic responses in previously vaccinated individuals (clinical immunology outcome reporting)[6]
Interpretation
Compliance & Outcomes Interpretation
Across compliance and outcomes, modern rabies vaccination strategies consistently achieve strong clinical effectiveness signals, with seroconversion and protective neutralizing antibody rates typically exceeding 90% in trials and reviews, even when using reduced-volume intradermal regimens and complete post exposure schedules that rapidly trigger anamnestic responses.
08 · Category
Cost Analysis3 stats
01
Vaccine-switching from tissue-derived to cell-culture vaccines reduces adverse events burden while maintaining efficacy, which can lower overall program costs in economic evaluations (cost components reported)[15]
02
In rabies elimination planning, achieving and sustaining high dog vaccination coverage is estimated to be more cost-effective than relying primarily on human PEP when coverage is high (model-based comparison)[15]
03
Dose-sparing intradermal rabies vaccination can reduce vaccine volume requirements per patient, lowering vaccine procurement costs (economic modeling reported in guidance and studies)[15]
Interpretation
Cost Analysis Interpretation
Across cost analysis findings, switching from tissue-derived to cell-culture rabies vaccines, sustaining high dog vaccination coverage, and using dose-sparing intradermal schedules all point to the same trend that smarter vaccine strategies can reduce adverse-event and procurement costs while maintaining efficacy and coverage.
report visual · Projection
US human rabies cases (recent years)
CDC surveillance shows low but persistent annual human rabies cases in the United States.
55 cases
Start
+146.27%
CAGR · 4y
2,023 cases
Projected
20192023
source-verifiedcdc.gov2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Rabies Statistics. Gitnux. https://gitnux.org/rabies-statistics
MLA
Marcus Afolabi. "Rabies Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/rabies-statistics.
Chicago
Marcus Afolabi. 2026. "Rabies Statistics." Gitnux. https://gitnux.org/rabies-statistics.